Moura DS, Lopez-Marti J, Tawbi H, Keung E, Wani K, Lazar A, Wang WL, Ingram DR, Meza-Zepeda LA, Myklebost O, Burgess M, Mondaza-Hernandez JL, Hindi N, Martín-Broto J (2026)
Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in patients with Sarcoma (SIGNIOS)
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-25-2580, PubMed 41537707

Heinrich MC, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg JR, Jones RL, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Boye K, Goldstein D, Sánchez C, Siontis BL, Cox P, Davis E, Sherman ML, Ruiz-Soto R, Bauer S (2025)
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
J Clin Oncol, 43 (20), 2239-2244
DOI 10.1200/JCO-24-02818, PubMed 40408605

Bjørnerud B, Wesche J, Haugsten EM (2025)
A rhabdomyosarcoma cell migration inhibitor screen using phase-contrast microscopy
Exp Cell Res, 449 (1), 114582
DOI 10.1016/j.yexcr.2025.114582, PubMed 40320199